Webinars and Commercial Conversations — Register Now
Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
Sysmex
| Company | Sysmex |
|---|---|
| Instrument name | Sysmex CN-3000 |
| Contact | Krishna Ram |
| City State | Lincolnshire, IL |
| Phone | 888-879-7639 |
| Website | |
| First year sold | 2025† |
| List price/Model type | —/floor standing |
| Dimensions (H × W × D)/Weight/Instrument footprint | 53.1 × 23.4 × 35.7 in./507 lbs./7.0 sq. ft. |
| No. of units in clinical use in U.S./Outside U.S. | —/>2, 300 (available in most countries) |
| Composition of installs: Hospital lab/Reference lab/Other | 95%/5%/— |
| Targeted daily, monthly, annual test volume | daily: 25–300; monthly: 750–9, 000; annual: 9, 000–110, 000 |
| Operational type | continuous random access |
| Country where analyzer designed/Manufactured | Japan/Japan |
| Company manufactures instrument | yes |
| FDA-approved clotting-based tests | PT, APTT, fibrinogen, factor VIII, factor IX, factor V, factor VII, factor V Leiden |
| FDA-approved chromogenic tests | antithrombin |
| FDA-approved immunologic tests | D-dimer |
| Other FDA-approved tests | — |
| User-defined tests in clinical use | factor XIII chromogenic RUO, platelet aggregation testing RUO |
| Tests in development or awaiting FDA 510(k) clearance | heparin (UFH and LMWH), apixaban, thrombin time, reptilase time, factor II, factor X, factor XI, factor XII, factor VIII (chromogenic), vWF activity (GP1bM), vWF antigen lupus screen, more |
| Methodologies supported | clot detection, optical; turbidimetric; chromogenic; immunologic (immunoturbidimetric) |
| Number of different measured assays onboard simultaneously | 60 |
| Number of different assays programmed and calib. at one time | 60 |
| No. of user-definable (open) channels/No. active simultaneously | 80, 000/60 |
| Factor assays require manual manipulation or dilutions | — |
| Test throughput per hour/Assay run time | 225 (1 test in throughput)/1–9 min. (avg. 4.5 min.) |
| Design of sample-handling system | 6-tube position sample rack with a maximum of 20 × racks |
| Operates on whole blood or spun plasma | spun plasma |
| Reagent type | self-contained single-use vials; open reagent system (liquid, lyophilized [reconstituted manually]) |
| Reagent barcode-reading capability | yes, for all tests |
| No. of reagent containers held onboard/Reagents ready to use | 44/variable (reagent specific) |
| Reagent lot tracking/Reagent inventory/Reagents refrigerated onboard | yes/yes/yes (10°C ± 2°C) |
| Reagents, consumables loaded without interrupting testing | yes (reagents and consumables) |
| Instrument uses proprietary or third-party reagents | user’s option (same capabilities when third-party reagents used) |
| Maximum time same lot number of reagents can be used | up to 36 months |
| Walkaway capability/Walkaway duration | yes/1, 140 min. or 120 specimens or 1, 200 tests |
| Min.–max. specimen volume that can be aspirated at one time | 5–500 µL |
| Min. sample volume required for PT/PTT/Factor VIII activity | 50 µL/50 µL/5 µL (standard) |
| Types of disposables used | reaction cuvettes, CN-Coagwasher, CA clean II |
| Primary tube sampling supported/Pierces caps on primary tubes | yes/yes |
| Accommodates most standard tube sizes/Nonstandard sizes | yes/yes (11.5 × 66 mm) |
| Sample barcode-reading capability/Autodiscrimination | yes (Interleaved 2 of 5, Codabar, Code 39, Code 128, JAN-8, JAN-13, ISBT-128)/yes |
| Auto tracks product volume/Measures number of tests remaining | yes/yes |
| Short sample detection | yes |
| Clot detection as preanalytical variable in plasma sample | yes |
| Auto detects adequate reagents for aspiration or analysis | yes (aspiration and analysis) |
| Detection or quantitation for hemolysis, turbidity, icterus, lipemia | detection and quantitation for hemolysis, turbidity, lipemia; detection for icterus |
| Dilutes patient samples onboard | yes |
| Automatic rerun capability/Auto reflex testing capability | yes/yes |
| Lag time during which hypercoagulable sample not detected | yes (PT: 7 seconds; PTT: 15 seconds) |
| User can adjust reagent volumes/Sample volumes | yes/yes |
| User can adjust No. of reagents/Sources of reagents | yes/yes |
| User can adjust incubation times/Reading times | yes/yes |
| Autocalibration/Calibrants stored onboard | yes/yes |
| Multipoint calibration supported/Recommended frequency | yes/6 months, per regulatory guidelines |
| • PT alone | <5 minutes/225 specimens |
| • PT, PTT | <5 minutes/215 specimens |
| • Fibrinogen | <5 minutes/225 specimens |
| • Factor VIII activity assay | <5 minutes/225 specimens |
| • D-dimer | <5 minutes/225 specimens |
| Time delay from ordering stat to aspiration of sample | <1 minute |
| How labs get LOINC codes for results | website |
| Onboard real-time QC/Onboard software capability to review QC | yes/yes |
| Information that can be barcode-scanned on instrument | operator identifier, specimen identifier, reagent lot No., reagent vial ID, reagent expiry |
| Compatible with laboratory automation systems | yes (Roche, Inpeco) |
| Data-management capability/LIS or EHR systems interfaced | onboard; optional add-on (Bio-Rad Unity Next Peer QC)/most major vendors |
| Interface supplied by instrument vendor | contract dependent |
| Results transferred to LIS as soon as test time complete | yes |
| Bidirectional interface capability | yes (host query) |
| Remote servicing provided/UPS backup power supply | yes/yes |
| Instrument connections to transfer information | data-management system, which in turn connects to LIS or EHR; data-management system that cannot further transmit data; directly to LIS or EHR; directly to lab automation system |
| Interface standards supported | ASTM 1394-91, ASTM 1381, HL7 |
| Information transferred to data-management software | device unique identifier, operator ID, patient ID, specimen ID, result, QC identifier, PSI checks |
| Avg. time for basic user training | 1–10 days (at customer site or vendor office), virtual instructor-led training also available |
| Approximate scheduled maintenance time | daily: <3 minutes; weekly: <3 minutes; monthly: none |
| Maintenance records kept onboard | yes |
| Warranty with purchase/Annual service contract cost (24/7) | yes/— (cost dependent on contract) |
| Distinguishing features (supplied by company) | ensures quality results with customizable preanalytical checks and simultaneous multiwavelength detection technology; maximizes walkaway time with the release capacity of sample loading; minimal maintenance ensures maximum uptime<br> |